US/UK/Canada

Share

Quotes

Take the opportunity to listen to, mingle with and maybe even pitch to industry experts, business developers, financing professionals and investors on every level. We offer a dynamic atmosphere allowing for spontaneous meetings between interested parties.
BioStock
Take the opportunity to listen to, mingle with and maybe even pitch to industry experts, business developers, financing professionals and investors on every level. We offer a dynamic atmosphere allowing for spontaneous meetings between interested parties.
BioStock
Take the opportunity to listen to, mingle with and maybe even pitch to industry experts, business developers, financing professionals and investors on every level. We offer a dynamic atmosphere allowing for spontaneous meetings between interested parties.
BioStock
Take the opportunity to listen to, mingle with and maybe even pitch to industry experts, business developers, financing professionals and investors on every level. We offer a dynamic atmosphere allowing for spontaneous meetings between interested parties.
BioStock
Take the opportunity to listen to, mingle with and maybe even pitch to industry experts, business developers, financing professionals and investors on every level. We offer a dynamic atmosphere allowing for spontaneous meetings between interested parties.
BioStock
The importance of having access to future-proof production is illustrated, among other things, by Bayer’s acquisition of AskBio and their advanced production method, and this is precisely the production method we have access to through our agreement with Viralgen, which was originally founded by AskBio. All in all, the activities we carried out during the year have significantly moved our positions forward
Jan Nilsson, CEO CombiGene
Pick a time period -
Tags ( Active)

China focus as AstraZeneca reports

A falling share price and an investigation involving personnel in China take center stage as AstraZeneca releases its third-quarter report. Despite these challenges, the underlying business remains robust. Strong performance across all segments has prompted the pharmaceutical giant to raise its full-year forecast.Read the full article at biostock.se : https://www.biostock.se/en/2024/11/china-focus-as-astrazeneca-reports/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Join the BioStock Life Science Summit on November 20 & 21!

At the seventh annual BioStock Life Science Fall Summit, 30+ life science companies will showcase their projects and business cases to investors and potential partners. The event will also offer thought-provoking insights from industry leaders and expert investors. Significant players from all aspects of the life science ecosystem will attend, and we anticipate highly rewarding networking. The Summit connects innovation and capital, providing small-to-medium cap Nordic companies from a wide range of therapeutic areas the platform and opportunity to make their case to both Swedish

GLP-1 and Keytruda steamed ahead in Q3

The report season is in full bloom. In the Big Pharma space, diabetes and obesity remain in focus during the third quarter, while world leader Keytruda enjoys a continued success story. BioStock has taken a closer look at the period.Read the full article at biostock.se : https://www.biostock.se/en/2024/11/glp-1-and-keytruda-steamed-ahead-in-q3/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

BioStock meets industry experts at BIO-Europe

The partnering event BIO-Europe has been a vital hub for the life science industry, fostering knowledge exchange and networking for three decades. This year, delegates gather in Stockholm, and BioStock is on-site as a media partner, connecting with company leaders, innovators, and experts.Read the article at biostock.se: https://www.biostock.se/en/2024/11/biostock-meets-industry-experts-at-bio-europe/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

EBD Group’s Bio-Europe event celebrates its 30th anniversary

The annual Bio-Europe partnering conference provides a platform for industry leaders to network and exchange ideas. This year marks the 30[th] anniversary, which will be celebrated with great fanfare in Stockholm on November 4-6. BioStock will be there, and to better understand what to expect, we talked to Claire Macht, Portfolio Director at EBD Group, who manages BIO-Europe.Read the full article at biostock.se : https://www.biostock.se/en/2024/11/ebd-groups-bio-europe-event-celebrates-its-30th-anniversary/ This is a press release from BioStock -

Positive momentum for newly listed biotech companies

After years of hibernation, biotech IPOs gained fresh momentum in 2024. But how has the market welcomed the newly listed companies, and what does this reveal about the current interest in the sector? BioStock has taken a closer look.Read the full article at biostock.se : https://www.biostock.se/en/2024/10/positive-momentum-for-newly-listed-biotech-companies/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Lundbeck makes huge bid for Longboard

Danish Lundbeck has made a bid for American Longboard Pharmaceuticals worth USD 2.6 billion. With this deal, they would get access to Bexicaserin, a promising treatment for severe epilepsy syndromes. Lundbeck shares are rising on the news.Read the full article at biostock.se : https://www.biostock.se/en/2024/10/lundbeck-makes-huge-bid-for-longboard/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

BioStock met industry leaders at LSX

This week, BioStock attended LSX Nordic in Copenhagen, a congress dedicated to showcasing innovation, cultivating investment, and fostering partnerships in Northern Europe’s life science ecosystem. Watch our interviews from the conference floor, where we engaged with industry experts.See all interviews at biostock.se : https://www.biostock.se/en/2024/10/biostock-met-industry-leaders-at-lsx/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Lower up-front payments for startups

The boom in biotech has had multiple impacts on early development companies. The lack of funding has forced many to tighten their belts, and several actors have even had to throw in the towel. But how has the new environment affected the prospects for partner agreements?Read the full article at biostock.se : https://www.biostock.se/en/2024/10/lower-up-front-payments-for-startups/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

The most shorted life science stocks in the Nordic region

US interest rate cuts are drawing ever closer and are expected to ease the pressure on a hard-pressed life science sector. However, not everyone is hoping for price increases. BioStock has listed the most shorted stocks in the industry and taken a closer look at some of the cases.Read the full article at biostock.se : https://www.biostock.se/en/2024/09/the-most-shorted-life-science-stocks-in-the-nordic-region/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Interviews with key players at Investing in Life Science

When BioStock, in collaboration with Vator Securities, organized the “Investing in Life Science: From Seed to Success” event, investors and entrepreneurs gathered to explore critical investment stages during a product’s development and life cycle. Amid the jam-packed stage program, we interviewed some of the industry’s leading players.See the interviews at biostock.se : https://www.biostock.se/en/2024/09/interviews-with-key-players-at-investing-in-life-science/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Investing in life science: From Seed to Success 2024

Last week, investors and entrepreneurs gathered at the World Trade Center in Stockholm for our “Investing in Life Science: From Seed to Success” event co-hosted by Vator Securities. The event brought together leaders in the life science industry to explore the critical stages of investment, from early seed funding to growth and strategic expansion.See the recorded event at biostock.se : https://www.biostock.se/en/2024/09/investing-in-life-science-from-seed-to-success-2024/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.

Danish pole position among best Nordic life science stocks in H1

The first six months of 2024 have passed and it is time to swap the ergonomically designed office chair for a sunbed At BioStock, it is also time for a half-year review to see which life science stocks have fared best so far this year. How have investors placed their bets going into H2?Read the full article at biostock.se : https://www.biostock.se/en/2024/07/danish-pole-position-among-best-nordic-life-science-stocks-in-h1/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Watch all videos from BioStock Global Forum 2024

On May 29-30, BioStock hosted the Global Forum. The event is the first of its kind, aimed at bringing together growth stage Nordic life science companies looking to expand into new markets and experts armed with a profound knowledge of how business is done across the globe. Check out the highlights from the event here!Watch all videos from Global Forum at biostock.se: https://www.biostock.se/2024/06/biostock-global-forum-2024/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

Flerie makes its way to the stock market via InDex

The chess pieces have long been in place for Flerie Invest, and now the specialist investor will enter the stock market through reverse acquisition by InDex Pharmaceuticals. – This is an important step in our plan to create a new model for life science investments, says Flerie CEO Ted Fjällman.Read the full article at biostock.se : https://www.biostock.se/en/2024/05/flerie-makes-its-way-to-the-stock-market-via-index/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

The best years in venture capital overlap perfectly with big crises | Health & Wealth #12

Søren Lemonius, founder and managing partner at Sunstone Life Science Ventures, shares the story of how he and his team initiated the Danish VC firm’s investment strategy that has lead to a number of very successful exits – and to some very costly losses. He also reveals why early-stage deals often yield the best returns (”because you’re selling a multiple of a dream”), explains why venture capital thrives in times of crisis and shares the one major reason for why some investments never materialise. We ponder the concept of longevity and find out what Søren considers to be the next hot areas

Earthquakes, investing in drugs and how to be decent in Venture Capital | Johan Kördel, Sound Bioventures | Health & Wealth #11

When Johan Kördel, a seasoned investor and managing partner at Swedish venture capital firm Sound Bioventures, suddenly woke up during an earthquake, he knew exactly what to do, yet he did nothing. Luckily, he lived to tell us the earthquake story, and much more! In this episode of Health & Wealth we talk about the dangers of doing nothing as a leader, the importance of risk management and why a portfolio approach is key when you invest in drug development. We also dive into his best investments (and a truly eye-popping exit!), learn about raising a billion SEK fund during a pandemic (hint:

Clinical trials: What to know before you invest | Health & Wealth #9 (Episode in English)

When developing new therapies or medicines, there are many hurdles along the way to reaching the market. If you do, that is. Failure is lurking at every step. A drug candidate must be safe and show clinicial efficacy in patients without severe side effects. The risks are significant and so are the costs, but if a project is successful, the reward could be enormous. So, how can you assess the risks involved?In this episode of Health & Wealth Jesper Prior Larsen from Aixial Group – a leading experts at clinical trials – walk us through some of the things you need to be aware of before

U.S. biotechs raises more capital

The capital drought for biotech companies in recent years has probably not escaped anyone. Now, however, we are getting hopeful signals from the U.S. The Financial Times reports that U.S. biotech companies managed to raise a total of USD 6.2 billion in January, which is the highest number in a single month since February 2021, when biotech was at its peak.Read the full article at biostock.se : https://www.biostock.se/en/2024/02/u-s-biotechs-raises-more-capital/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Nasdaq introduces auction trading on First North

Nasdaq has implemented a new trading model for shares with limited liquidity on Nasdaq First North Growth Market. The model came into effect today January 18 and means that stocks with large spreads between bid and asking prices will be traded through auctions instead of continuous trading. One company in the life science sector that is affected by the new model is Cline Scientific.Read the full article at biostock.se : https://www.biostock.se/en/2024/01/nasdaq-introduces-auction-trading-on-first-north/ This is a press release from BioStock - Connecting

2023’s strongest and weakest life science stocks

Now that we have entered the new year, it is time to sum up 2023 on the stock market. BioStock has listed last year’s strongest and weakest life science stocks and taken a closer look at a couple of companies that stand out.Read the full article at biostock.se : https://www.biostock.se/en/2024/01/2023s-strongest-and-weakest-life-science-stocks/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

All sessions from BioStock Life Science Fall Summit 2023

On October 25-26, we hosted the sixth consecutive BioStock Life Science Fall Summit - watch all the sessions below. Over 40 companies in various therapeutic areas presented their projects and innovations. The programme also included pitches from unlisted companies, panel discussions, and interviews.Watch all the sessions from the event at biostock.se:https://www.biostock.se/en/2023/10/biostock-life-science-fall-summit-2023/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Video from day 2 of BioStock Life Science Fall Summit 2023

During this year’s BioStock Life Science Fall Summit, more than 40 companies in many therapeutic areas had the opportunity to talk about their projects, innovations, and prospects. The program included pitches from unlisted companies, panel discussions, and interviews. See all the features from the second event day below.Read the full article and watch the presentations at biostock.se: Video from day 2 of BioStock Life Science Fall Summit 2023  This is a press release from BioStock -

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe